

8 March 2021

**Diaceutics PLC**  
**("Diaceutics" or the "Company")**

**Notice of results**  
***Analyst & investor briefing***

Diaceutics PLC (AIM: DXRX), announces it will release its preliminary results for the year ended 30 December 2020 on Monday, 15 March 2021.

**Analyst briefing**

The Company will host a ZOOM briefing for analysts which will take place at 9.30am on Monday, 15 March 2021. If you would like to register to dial in, please contact Walbrook PR on 020 7933 8780 or email [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com).

**Investor briefing**

Peter Keeling, CEO and Philip White, CFO will provide a live presentation on the preliminary results via the Investor Meet Company platform at 3pm on Wednesday, 17 March 2021.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Diaceutics PLC via:

<https://www.investormeetcompany.com/diaceutics-plc/register-investor>

Investors who already follow Diaceutics PLC on the Investor Meet Company platform will automatically be invited.

**Enquiries:**

**Diaceutics PLC**

Peter Keeling, Chief Executive Officer  
Philip White, Chief Financial Officer

[www.diaceutics.com](http://www.diaceutics.com)  
*via Walbrook PR*

**Cenkos Securities plc (Nominated adviser and broker)**

Callum Davidson / Giles Balleny  
Michael Johnson (Sales)

+44 (0) 20 7391 8900

**Walbrook PR**

Anna Dunphy  
Paul McManus

Tel: +44 (0)20 7933 8780 or [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com)  
Mob: +44 (0)7876 741 001  
Mob: +44 (0)7980 541 893

**About Diaceutics**

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world's first Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Group, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. [www.diaceutics.com](http://www.diaceutics.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORUVVSRAWUORAR